Form 4 for EW Edwards Lifesciences
Accepted 2025-05-06 00:00:00 ET · period of report 2025-05-03 · accession 0001225208-25-004799 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-05-06 | 2025-05-03+ | EW | Zovighian Bernard J | CEO, Dir | F - Tax | $75.65 | -1,070 | 58.8K | -2% | -$80.9K |
| D | 2025-05-06 | 2025-05-05 | EW | Zovighian Bernard J | CEO, Dir | M - OptEx | $45.28 | +7,462 | 65.7K | +13% | +$337.9K |
| DM | 2025-05-06 | 2025-05-05+ | EW | Zovighian Bernard J | CEO, Dir | G - Gift | $0.00 | -2,518 | 57.2K | -4% | $0 |
| DMI | 2025-05-06 | 2025-05-05+ | EW | Zovighian Bernard J | CEO, Dir | G - Gift | $0.00 | +2,518 | 13.0K | +24% | $0 |
| D | 2025-05-06 | 2025-05-05 | EW | Zovighian Bernard J | CEO, Dir | S - Sale+OE | $74.91 | -5,980 | 58.3K | -9% | -$448.0K |
| D | 2025-05-06 | 2025-05-05 | EW | Zovighian Bernard J | CEO, Dir | M - OptEx | $0.00 | -7,462 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-04 | F | D | 543 | $75.65 | 58,283.55 | D By Trust | — | — | |
| 2 | Common | Common Stock | 2025-05-05 | M | A | 7,462 | $45.28 | 65,745.55 | D | — | — | |
| 3 | Common | Common Stock | 2025-05-05 | G | D | 1,482 | $0.00 | 64,263.55 | D | — | — | |
| 4 | Common | Common Stock | 2025-05-06 | G | D | 1,036 | $0.00 | 57,247.55 | D | — | — | |
| 5 | Common | Common Stock | 2025-05-05 | G | A | 1,482 | $0.00 | 11,918 | I | — | — | |
| 6 | Common | Common Stock | 2025-05-06 | G | A | 1,036 | $0.00 | 12,954 | I | — | — | |
| 7 | Common | Common Stock | 2025-05-03 | F | D | 527 | $75.65 | 58,826.55 | D By Trust | — | — | |
| 8 | Common | Common Stock | 2025-05-05 | S | D | 5,980 | $74.91 | 58,283.55 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $74.67 to $75.15 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 9 | Derivative | Employee Stock Option (Right to Acquire) | 2025-05-05 | M | D | 7,462 | $0.00 | 0 | D | $45.28 · — to 2025-05-16 | 7,462 Common Stock | (F3) These options were granted on May 17, 2018 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one yearafter the grant date in four equal annual installments. |